Fetal gene therapy’s progress calls into question the taboo on embryo editingnews2026-05-20T14:10:34+00:00May 20th, 2026|Endpoints News|
#ASGCT26: A Zillow-like marketplace for abandoned gene therapies goes livenews2026-05-15T10:45:33+00:00May 15th, 2026|Endpoints News|
Encoded’s gene therapy reduced seizures in Dravet syndromenews2026-05-14T18:50:34+00:00May 14th, 2026|Endpoints News|
ASGCT dispatch: In vivo CAR-T is everywherenews2026-05-14T18:24:17+00:00May 14th, 2026|Endpoints News|
Regenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approvalnews2026-05-14T11:00:17+00:00May 14th, 2026|Endpoints News|
After an apparent cure, a gene editing company struggles to repeat the magicnews2026-05-13T18:50:53+00:00May 13th, 2026|Endpoints News|
Tessera reveals strongest data yet for in vivo sickle cell therapynews2026-05-13T12:00:56+00:00May 13th, 2026|Endpoints News|
Flagship startup Serif says it has solved non-viral gene therapy in monkeysnews2026-05-12T10:00:42+00:00May 12th, 2026|Endpoints News|
European regulators greenlight Fractyl Health’s clinical test of GLP-1 gene therapynews2026-05-11T11:00:40+00:00May 11th, 2026|Endpoints News|
Atara, Pierre Fabre’s cell therapy to get another shot at FDA approvalnews2026-05-07T13:17:55+00:00May 7th, 2026|Endpoints News|
